Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination
2024/08/01 by William N. Voss, Michael L. Mallory, Patrick O. Byrne +22 · 1 voice · 26 citations
Medicine · Immunology and Microbiology · #Blood groups and transfusion #Immunodeficiency and Autoimmune Disorders #SARS-CoV-2 and COVID-19 Research
paper · doi:10.1016/j.xcrm.2024.101668
Abstract
We describe the molecular-level composition of polyclonal immunoglobulin G (IgG) anti-spike antibodies from ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, vaccination, or their combination (“hybrid immunity”) at monoclonal resolution. Infection primarily triggers S2/N-terminal domain (NTD)-reactive antibodies, whereas vaccination mainly induces anti-receptor-binding domain (RBD) antibodies. This imprint persists after secondary exposures wherein >60% of ensuing hybrid immunity derives from the original IgG pool. Monoclonal constituents of the original IgG pool can increase breadth, affinity, and prevalence upon secondary exposures, as exemplified by the plasma antibody SC27. Following a breakthrough infection, vaccine-induced SC27 gained neutralization breadth and potency against SARS-CoV-2 variants and zoonotic viruses (half-maximal inhibitory concentration [IC50] ∼0.1–1.75 nM) and increased its binding affinity to the protective RBD class 1/4 epitope (dissociation constant [KD] < 5 pM). According to polyclonal escape analysis, SC27-like binding patterns are common in SARS-CoV-2 hybrid immunity. Our findings provide a detailed molecular definition of immunological imprinting and show that vaccination can produce class 1/4 (SC27-like) IgG antibodies circulating in the blood.
Cited by
- Structural Immunology of SARS‐CoV‐2
- Detrimental Effects of Anti-Nucleocapsid Antibodies in SARS-CoV-2 Infection, Reinfection, and the Post-Acute Sequelae of COVID-19
- Risk and Protective Factors for Infection, Severe Disease, and Mortality in Epidemic Respiratory Viruses
- Engineering a SARS-CoV-2 Vaccine Targeting the Receptor-Binding Domain Cryptic-Face via Immunofocusing. [europepmc]
- Structural Immunology of SARS-CoV-2. [europepmc]
- Detrimental Effects of Anti-Nucleocapsid Antibodies in SARS-CoV-2 Infection, Reinfection, and the Post-Acute Sequelae of COVID-19. [europepmc]
- Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia. [europepmc]
- Serum proteomics reveals high-affinity and convergent antibodies by tracking SARS-CoV-2 hybrid immunity to emerging variants of concern. [europepmc]
- Receptor Binding for the Entry Mechanisms of SARS-CoV-2: Insights from the Original Strain and Emerging Variants. [europepmc]
- Impact of Prior SARS-CoV-2 Infection on COVID-19 Vaccine Effectiveness in Children and Adolescents in Norway and Italy. [europepmc]
- Vaccination, infection, and hybrid immunity: determinants of SARS-CoV-2 IgG antibody levels and protection in Quzhou, China. [europepmc]
- Immune counter-evolution: immortalized B cell clones can undergo ex vivo directed evolution to counteract viral escape. [europepmc]
- Herd Immunity to SARS-CoV-2 Among the Armenian Population in the Second Half of 2022. [europepmc]
- Computationally designed mRNA-launched protein nanoparticle immunogens elicit protective antibody and T cell responses in mice. [europepmc]
- Quantification of the IgG antibody response half-life for hybrid immunity to SARS-CoV-2. [europepmc]
- 400 AU/mL IgG protective threshold against SARS-CoV-2 XBB reinfection in Chinese inactivated vaccine recipients: implications for booster vaccination. [europepmc]
- Mining antibody functionality via AI-guided structural landscape profiling. [europepmc]
- Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human V H 1-2-rearranging mouse models. [europepmc]
- Target Trial Emulation of Vaccine Effectiveness in 5- to 17-years-olds with Prior SARS-CoV-2 Infection. [europepmc]
- SARS-CoV-2 Variants and Immune Evasion: Mapping the Future of Vaccine Design. [europepmc]
- The Effects of Past COVID-19 and Vaccination on Antibody Levels, Cellular Immunity, and Cytokine Production by Peripheral Blood Mononuclear Cells. [europepmc]
- NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants. [europepmc]
- A cocktail of SARS-CoV-2 S stem helix domain and receptor binding domain human monoclonal antibodies prevents the emergence of viral escape mutants. [europepmc]
- SARS-CoV-2 Omicron infection reveals imprinted antibody responses in the absence of vaccination. [europepmc]
- SARS-CoV-2 infection imprints neutralising antibody responses in the absence of vaccination [europepmc]
- Systematic benchmarking of mass spectrometry-based antibody sequencing reveals methodological biases [europepmc]
Discussions
Related